Cargando…

Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics

AFN-1252, a potent enoyl-ACP reductase (FabI) inhibitor, is under development for the treatment of Staphylococcus aureus infections. The activity of AFN-1252 against two isolates of S. aureus, MSSA 26213 and MRSA S186, was studied in an in vitro pharmacodynamic model simulating AFN-1252 pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuji, Brian T, Harigaya, Yoriko, Lesse, Alan J, Forrest, Alan, Ngo, Dung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Maney Publishing 2013
Materias:	Antimicrobial Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558987/ https://www.ncbi.nlm.nih.gov/pubmed/23433442 http://dx.doi.org/10.1179/1973947812Y.0000000060

Ejemplares similares

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model
por: Banevicius, Mary A, et al.
Publicado: (2013)

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics
por: Kaplan, Nachum, et al.
Publicado: (2013)

Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression
por: Grandgirard, Denis, et al.
Publicado: (2015)

Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus
por: Harigaya, Yoriko, et al.
Publicado: (2011)

Nonactive-Site Mutations in S. aureus FabI That Induce Triclosan Resistance
por: Demissie, Robel, et al.
Publicado: (2020)

Staphylococcus aureus but not Listeria monocytogenes adapt to triclosan and adaptation correlates with increased fabI expression and agr deficiency
por: Nielsen, Lene Nørby, et al.
Publicado: (2013)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Correlating drug–target kinetics and in vivo pharmacodynamics: long residence time inhibitors of the FabI enoyl-ACP reductase
por: Daryaee, Fereidoon, et al.
Publicado: (2016)

SaeR as a novel target for antivirulence therapy against Staphylococcus aureus
por: Gao, Peng, et al.
Publicado: (2023)

Methicillin-resistant Staphylococcus aureus in China: a multicentre longitudinal study and whole-genome sequencing
por: Wang, Bingjie, et al.
Publicado: (2022)

Molecular Modelling Study and Antibacterial Evaluation of Diphenylmethane Derivatives as Potential FabI Inhibitors
por: Hasan, Shaima, et al.
Publicado: (2023)

The novel fosfomycin resistance gene fosY is present on a genomic island in CC1 methicillin-resistant Staphylococcus aureus
por: Chen, Yiyi, et al.
Publicado: (2022)

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach
por: Garonzik, Samira M., et al.
Publicado: (2016)

Antibiotic resistance profiles and population structure of disease-associated Staphylococcus aureus infecting patients in Fort Portal Regional Referral Hospital, Western Uganda
por: Ackers-Johnson, Gavin, et al.
Publicado: (2021)

Phylogenetic analysis and virulence characteristics of methicillin-resistant Staphylococcus aureus ST764-SCCmec II: an emerging hypervirulent clone ST764-t1084 in China
por: Xiao, Yanghua, et al.
Publicado: (2023)

Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens
por: Parker, Erica N., et al.
Publicado: (2019)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Meleagrin, a New FabI Inhibitor from Penicillium chryosogenum with at Least One Additional Mode of Action
por: Zheng, Chang Ji, et al.
Publicado: (2013)

Pharmacophore and Molecular Docking Guided 3D-QSAR Study of Bacterial Enoyl-ACP Reductase (FabI) Inhibitors
por: Lu, Xiaoyun, et al.
Publicado: (2012)

Drug-likeness prediction of designed analogues of isoniazid standard targeting FabI enzyme regulation from P. falciparum
por: Pandey, Anil Kumar, et al.
Publicado: (2019)

Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020)

Simulated Comparison of a Bayesian Clinical Decision Support System Versus Standard of Care For Achieving Gentamicin Pharmacokinetic Targets in Neonates
por: Yu, Collin Z., et al.
Publicado: (2020)

Methicillin-Resistant Staphylococcus aureus in the Oral Cavity: Implications for Antibiotic Prophylaxis and Surveillance
por: Donkor, Eric S, et al.
Publicado: (2020)

Ligand‐ and Structure‐Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence
por: Kronenberger, Thales, et al.
Publicado: (2019)

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
por: Domachowske, Joseph B., et al.
Publicado: (2018)

E. coli ST11 (O157:H7) does not encode a functional AcrF efflux pump
por: Pugh, Hannah L., et al.
Publicado: (2023)

Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Leonard, Steven N.
Publicado: (2012)

Dose Assessment of Cefquinome by Pharmacokinetic/Pharmacodynamic Modeling in Mouse Model of Staphylococcus aureus Mastitis
por: Yu, Yang, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus
por: Rox, Katharina, et al.
Publicado: (2022)

571. Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship
por: Mergenhagen, Kari A, et al.
Publicado: (2019)

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae
por: Wicha, Wolfgang W, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX Against Staphylococcus aureus-Induced Mouse Peritonitis Model
por: Zheng, Xueling, et al.
Publicado: (2022)

973. Pharmacokinetic/Pharmacodynamic Evaluation and Dose Optimization of Daptomycin in Pediatric Patients with Staphylococcus aureus Bacteremia
por: Olney, Katie B, et al.
Publicado: (2023)

An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections
por: Parker, Erica N., et al.
Publicado: (2022)

Treatment of Spent Pickling Solutions by Diffusion Dialysis Using Anion-Exchange Membrane Neosepta-AFN
por: Bendová, Helena, et al.
Publicado: (2022)

Correction to “An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections”
por: Parker, Erica N., et al.
Publicado: (2022)

In Vivo Pharmacokinetics/Pharmacodynamics of Cefquinome in an Experimental Mouse Model of Staphylococcus Aureus Mastitis following Intramammary Infusion
por: Yu, Yang, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic Correlation of Cefquinome Against Experimental Catheter-Associated Biofilm Infection Due to Staphylococcus aureus
por: Zhou, Yu-Feng, et al.
Publicado: (2016)

Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece
por: Galani, Irene, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t8gn6kofp6o1riho7v8ao3dheo